Proteasome Inhibitor News and Research

RSS
Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

Onyx Pharmaceuticals reports positive Phase 2b 003-A1 study results of carfilzomib for refractory multiple myeloma

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

IMO-4200 dual agonist increases antitumor activity in lymphoma models: Study

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Clinical trial results of ACY-1215 in multiple myeloma published in scientific journal of ASH

Bortezomib reduces inflammation and promotes bone healing in arthritis models

Bortezomib reduces inflammation and promotes bone healing in arthritis models

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

Carfilzomib could become new option for patients with relapsed myeloma, IMF says

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

New study on impact of bortezomib on mantle cell lymphoma

New study on impact of bortezomib on mantle cell lymphoma

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Clinical trials of four investigational compounds in solid tumors presented at ASCO Annual Meeting

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Onyx reports encouraging ORR from ongoing Carfilzomib Phase 2 study for multiple myeloma

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

Onyx Pharmaceuticals announces presentations evaluating carfilzomib for multiple myeloma at 46th ASCO

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

John Theurer Cancer Center presents over 20 research updates and trial results at the 2009 ASH meeting

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Carfilzomib shows noteworthy responses and low side effects among multiple myeloma patients

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Bortezomib lymphoma drug may be effective against bone cancer in children and teens: Study

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix